At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Jun 4, 2026 at 16:05 ET
Lyell Immunopharma announced upcoming presentations of ronde-cel Phase 1/2 safety and translational data at the EHA 2026 Congress, but no clinical results were disclosed. The company's key catalysts remain the PiNACLE trial data expected in H2 2026 and a potential BLA submission in 2027. This is a routine pipeline update with no immediate impact.
- Ronde-cel safety and translational data to be presented at EHA 2026 (June 11-14).
- PiNACLE trial (3L+ LBCL) data expected H2 2026, pivotal data by mid-2027, BLA submission 2027.
- No new clinical data or financial guidance provided in this release.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access